Associated Papers
Discriminating activating, deactivating and resistance variants in protein kinases.
Singh G et al.
Genome Medicine, 2025
41152984 (PubMed )
Supplement: 13073_2025_1564_MOESM2_ESM.xlsx › Table_S6
Resistance to a tyrosine kinase inhibitor mediated by changes to the conformation space of the kinase.
Freire TS et al.
Physical Chemistry Chemical Physics : Pccp, 2023
Resistance to targeted therapies: delving into FLT3 and IDH.
Desikan SP et al.
Blood Cancer Journal, 2022
The Irreversible FLT3 Inhibitor FF-10101 Is Active Against a Diversity of FLT3 Inhibitor Resistance Mechanisms.
Ferng TT et al.
Molecular Cancer Therapeutics, 2022
Exploring the Resistance Mechanisms of Distal D835V Mutation in FLT3 to Inhibitors.
Wang Z et al.
Oxidative Medicine and Cellular Longevity, 2022
A noncanonical FLT3 gatekeeper mutation disrupts gilteritinib binding and confers resistance.
Joshi SK et al.
American Journal of Hematology, 2021
Gilteritinib overcomes lorlatinib resistance in ALK-rearranged cancer.
Mizuta H et al.
Nature Communications, 2021
Gilteritinib is a clinically active FLT3 inhibitor with broad activity against FLT3 kinase domain mutations.
Tarver TC et al.
Blood Advances, 2020
Pan-cancer whole-genome analyses of metastatic solid tumours.
Priestley P et al.
Nature, 2019
31645765 (PubMed )
Supplement: 41586_2019_1689_MOESM14_ESM.xlsx › Sheet1
ATP-Competitive Inhibitors Midostaurin and Avapritinib Have Distinct Resistance Profiles in Exon 17-Mutant KIT.
Apsel Winger B et al.
Cancer Research, 2019
Characterizing and Overriding the Structural Mechanism of the Quizartinib-Resistant FLT3 "Gatekeeper" F691L Mutation with PLX3397.
Smith CC et al.
Cancer Discovery, 2015
Select a paper to view details